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Poster Session I S209chemotherapy with rituximab, carmustine, etoposide, cytarabine and
melphalan. Adjuvant immunotherapy consisted of rituximab
375 mg/M2 IV weekly and sargramostim 250 ug s.c. TIW during
weeks 5 to 8 and 24 to 27 post transplant.
Results: Seven patients had successful mobilization (mean CD34/kg
collected 12.5E6 and infused 9E6) and underwent transplant. Me-
dian time to neutrophil and platelet engraftment was 9 and 10 days
respectively. Six patients are alive with no evidence of disease from
3 to 18 months post transplant. One patient relapsed at 11 months.
4/4 patients receiving at least once cycle of adjuvant immunotherapy
developed grade 1 to 4 neutropenia from 3 to 34 weeks post adjuvant
rituximab. Neutrophil counts recovered following treatment with
G-CSF, but recurred in all 4 patients without additional exposure
to rituximab. One patient who had engrafted platelets developed
grade 2 thrombocytopenia on day 33 post transplant. Platelets spon-
taneously recovered.
Conclusions: Delayed-onset neutropenia is a known complication
of rituximab. The incidence may be higher when rituximab is used
following ASCT. It is not clear if the timing of rituximab administra-
tion post transplant or the concomitant use of sargramostim contrib-
uted to the high incidence of delayed neutropenia in this study.
Larger studies and longer followup will be needed to determine if ad-
juvant immunotherapy decreases relapse.137
CONSOLIDATION THERAPY FOLLOWING AUTOLOGOUS STEM CELL
TRANSPLANTATION FOR NON-HODGKINS AND HODGKINS LYMPHOMAS
Colvin, G.A., Milani, C., Berz, D., Quesenberry, P. Brown University,
Providence, RI
Purpose: To determine whether autologous stem-cell transplanta-
tion (ASCT) followed by consolidation with Rituximab or irradia-
tion is superior to ASCT alone in adults with advanced or relapsed
lymphoma.
Patients and Methods: Fourteen consecutive lymphoma patients
were entered onto this prospective, single center, phase II study. Sev-
enteen previously transplanted patients were used as historical con-
trols with continuous follow-up. Patients with non-Hodgkin’s
lymphoma (NHL, n5 11) or Hodgkin’s disease (HD, n5 3) re-
ceived ASCT followed by consolidation with Rituximab (375 mg/
m2/week x4, every 6 months x5) or irradiation (20-30 Gy) respec-
tively.
Results: Age, diagnosis (NHL vs. HD), B symptoms, risk factors,
LDH, previous treatment response and histological type were well
balanced between the two groups. With a median follow-up of
21.3 months, the 30-month relapse rate was 23% and 53%
(P5 0.045), disease-free survival was 70% and 41% (P5 0.03) and
overall survival was 73% and 47% (P5 0.07) for the consolidation
group and historical controls, respectively. A multivariate analysis
showed that age$ 55 and abnormal pre-transplant LDH were pre-
dictors of poor outcome. When NHL patients were analyzed sepa-
rately (n5 24), 30-month relapse rate was 27% and 63%
(P5 0.08), disease free survival was 73% and 47% (P5 0.05) and
overall survival was 70% and 40% (P5 0.06) for consolidation and
control arms, respectively.
Conclusion: The use of ASCT followed by consolidation using Rit-
uximab (NHL) or irradiation (HD) in adults with advanced lym-
phoma showed a markedly decreased relapse rate and improved
disease free and overall survival compared with conventional
ASCT. The NHL subgroup (Rituximab) also demonstrated that
consolidation produced a marked advantage.138
COMBINED AMIFOSTINE AND CRYOTHERAPY FOR PREVENTION OF
ORAL MUCOSITIS (OM) FOLLOWING HIGH DOSE CHEMOTHERAPY
WITH MELPHALAN AND AUTOLOGOUS HEMATOPOIETIC CELL TRANS-
PLANT (HCT) FOR MULTIPLE MYELOMA (MM)
Lopez-Bover, M., Thompson, M., Santos, V., Holder, M., Feinstein, L.,
Grosman, D. Memorial Cancer Institute, Pembroke Pines, FLOM is a major cause of morbidity following autologous HCT
for MM. Amifostine is a free radical scavenger that reduces proin-
flammatory cytokine production. Cryotherapy causes vasoconstric-
tion of vessels in the oral cavity. Randomized controlled trials
have demonstrated a significant reduction in the severity and du-
ration of OM when amifostine or cryotherapy is administered
with high dose melphalan prior autologous HCT for MM. To
date, no report has been made of outcomes when both treatments
are used concurrently.
We performed 28 autologous HCTs on 21 patients with MM
in an outpatient setting. Patients received amifostine 740 mg/m2
24 hours prior to and immediately prior to melphalan (200 mg/
m2 for 19 patients and 140 mg/m2 for 2 patients; dose depen-
dent on renal function). Cryotherapy was administered for four
hours beginning 30 minutes prior to the administration of mel-
phalan. Six patients had a decline in systolic blood pressure
of$ 20% of baseline following the administration of amifostine.
Aggressive intravenous hydration and Trendeleberg positioning
resulted in the rapid return to baseline blood pressure in all
cases. Prehydration and holding antihypertensive medications
for 24 hours prior to the first dose of amifostine reduced symp-
tomatic hypotension.
No patient was admitted for OM. The one patient who required
both total parenteral nutrition and narcotic analgesics for grade III
OM did not remove his dentures during cryotherapy. One patient
experienced grade II OM that was managed with oral narcotic anal-
gesics. The remaining 19 patients experiencing either grade I (n5 1)
or no (n5 18) OM. Combined amifostine and cryotherapy is a well-
tolerated and effective method of reducing OM following high dose
melphalan and autologous HCT for MM.139
AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RE-
FRACTORY OR RELAPSED HODGKIN DISEASE IN COLOMBIA
Linares, A.1,2, Abello, V.1, Pedraza, E.1, Rosales, C.1, Rosales, M.1,
Esguerra, H.1, Figueroa, J.1, Rubio, A.2 1Clınica de Marly, Bogota, Co-
lombia; 2Universidad Nacional de Colombia, Bogota, Colombia
Objectives: The aim of this study is to report outcomes of patients
with Hodgkin Disease (HD) after high dose therapy and autologous
Hematopoietic Stem Cell Transplantation (auto-HSCT) in a single
center in Colombia.
Methods: One hundred four patients with relapsed or refractory
HD were treated with auto-HSCT between 1994 and 2008. Clinical
status previous to transplantation, and events as relapse or death were
analyzed to establish 5 year Overall Survival (OS) and Event Free
Survival (EFS).
Results: One hundred four patients have had 105 procedures (one
patient with 2 auto-SCT). Thirty-five female and 69 male, 79 adults
and 25 less than 16 years, with average age of 27.4 years (range 5 to 66
yrs). Forty-one patients (39,4%) with refractory disease, 21 with
early relapse (20%) and 42 with late relapse (40,4%).
Clinical stage at diagnosis: I and IIA 24 patients (23%), IIB 28 pa-
tients (26.9%), IIIA 7 patients (6.7%), III B 21 patients (20%), stage
IV 21 patients (20%) and (3 patients unknown). The source of cells
was peripheral blood in 95 transplants (91.4%), bone marrow in 6
(5.7%) and combined in 2 procedures (1.9%) combined, (2 patients
unknown).
The conditioning chemotherapy was BEAM in 56 transplants
(53.3%), cyclophosphamyde-etoposide-melphalan in 26 (24.7%)
and other protocols in 23 (21.9%) transplants. At the time of trans-
plantation, 61 patients (58%) were in complete remission, 36 (34%)
in partial remission and 5 (4.7%) with active disease.
Twenty nine patients had relapse, of them 11 are dead. Seven
patients had non relapse mortality: 5 with infectious complications,
1 with colecistitis and 1 with graft failure. Two patients died for
complications of a second neoplasm. The mortality in the first
100-days was 3% (3 patients with infectious complications).
With a median of 971 days of follow-up (range 12 to 5587
days), 59 (56.7%) patients are in complete remission, 17 (16.3%)
are alive after relapse, 21 (20.1%) have died and 7 (6.7%) were
lost for follow-up.
S210 Poster Session IConclusions: Near 50% of patients with refractory or relapsed HD
can be successfully treated with high dose chemotherapy and autol-
ogous stem cell transplantation.
It is important to have a longer follow up on these patients so we
can perform analysis on prognostic factors for relapse and survival.140
EVALUATING EFFECTIVENESS OF CHANGING THE ADMINISTRATION
TIME OF PLERIXAFOR ON PERIPHERAL CD 34 + CELL COUNTS
Johnson, M., Sirilla, J., Elder, P. OSU Medical Center-James Cancer
Hospital, Columbus, OH
Plerixafor has been shown to rapidly increase CD 34+ cells in
healthy volunteers alone or in combination with Neupogen (Fowler,
et al, 2009). The addition of Plerixafor to Neupogen results in a tri-
pling of circulating CD34+ cells 10 hours after administration
(Clerq, 2009).
At The Ohio State University Medical Center-James Cancer Hos-
pital, we initially administered Plerixafor at 10 p.m. (10 hours prior
to the start of Apheresis). Administering Plerixafor at this time cre-
ated some issues requiring attention. First, there is the issue of incon-
venience to the patient. The patient would come to the hospital at
9:45 p.m., get their dose, go home or to a local hotel, then return
to the hospital for Apheresis at 7:30 a.m. the following morning. Sec-
ondly, because the outpatient clinic closed at 5:00 p.m., the patient
would go to the inpatient unit and have the charge nurse administer
the Plerixafor. At times, the inpatient unit had no available rooms to
see the patient and observe for side effects, becoming a concern for
the inpatient nursing staff to monitor the patient appropriately. Be-
cause of these issues, our institution changed the administration time
of Plerixafor to 6:15 p.m. The outpatient clinic adjusted their clinic
hours to accommodate the need for patients receiving Plerixafor.
Currently, we have administered Plerixafor to 24 patients (2 pa-
tients were remobilized with Plerixafor) since the drug received
FDA approval in December, 2008. Nineteen patient received Plerix-
afor at 10 p.m. Of these, sixteen patients had an adequate peripheral
CD 34+ count (.10) allowing them to collect an adequate amount of
stem cells for transplant. Of the 5 patients that received Plerixafor at
6:15 p.m., 4 patients had an adequate peripheral CD 34+ cell count
to proceed to Apheresis.
Changing the time of Plerixafor to 6:15 p.m. aided in the overall
safety of the patient. It is less inconvenient for the patient to return
to the hospital in the early evening (during daylight hours) and it al-
lows for the outpatient nursing staff to address any issues in an appro-
priate setting.
Our institution is looking at other areas of improvement using
Plerixafor. We are currently using an algorithm in determining
which patients may not mobilize an adequate number of CD 34+
cells. Also, we are checking the peripheral CD 34+ cell count on
day 4 of Neupogen in patients that are coming to the hospital to
have their central line placed to assess the need for Plerixafor that
evening.141
NEED OF RECONSIDERATION OF MOBILIZATION STRATEGY IN AUTOLO-
GOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: RE-
SULTS OF THE POSITIVE IMPACT OF HIGH NUMBER OF
CD34 + INFUSED CELLS
Michallet, M.1, Sobh, M.1, Nicolini, F.E.1, Raus, N.1, Baracco, F.1,
Cannas, G.1, Chelghoum, Y.1, Clapisson, G.1, Thomas, X.1, Troncy, J.1,
Ducastelle, S.1 1Edouard Herriot Hospital, Lyon, France
This study concerned 130 MM patients who underwent ASCT in
our center between years 2000 and 2007. There were 79 males and 51
females with a median age of 56.8 years (34-72). Before transplanta-
tion, all patients received granulocyte-colony stimulating factor (G-
CSF) 5mg/kg/day, PBSC were mobilized in steady state in 135 cases,
62 after G-CSF + cyclophosphamide. As conditioning, all pts re-
ceived melphalan alone with a median total dose of 304 mg (130-
440). Sixty six patients received a single ASCT and 64 patients re-
ceived 2 ASCT in a double ASCT program. After transplantation,there were 2 graft failure, 40% of patients received red blood cell
(RBC) transfusions (median number: 0 [0-23]), and 64% received
platelet transfusions (median number: 1 [0-20]). The median number
of days with neutrophils\0.5 G/L was 6 (0-33) and with platelets
\20 G/L was 17 (2-104). The median length of hospitalization for
auto transplantation was 18 days (14-54). To assess the impact of
the infused CD34+ cells number, we have analyzed 2 groups: group
1 (n5 86) for ASCT with a number of CD34 +#3106/kg and
group 2 (n5 107) for ASCT with a number of CD34 +.3106/kg.
Results: We found a high significant impact of the high number of
infused CD34+(group 2) on platelets recovery (p5 0.002). The uni-
variate analysis using Cox model, showed a trend for the high num-
ber of infused CD34+ cells (group2) on leukocyte recovery
O.R5 0.748 [0.5-1.0] (p5 0.0568) and a high significant impact of
the same group on neutrophils recovery O.R5 0.670 [0.5-0.9]
(p5 0.009). These results were not changed even after adjustment
on age also on the sequential number of the ASCT in the double
auto ASCT program. The multivariate analysis using Cox model,
studying the impact of CD34+ group, age, gender, poor prognostic
factors [high level of b2microglobulin and del(13)], mobilization
(G-CSF alone or G-CSF + cyclophsphamide), showed a significant
impact only of poor prognostic factors on overall survival
O.R.5 7.94 [1.0-59.2] (p5 0.04) and also on progression free sur-
vival (PFS) O.R.5 2.55 [1.1-5.7] (p5 0.024).
Conclusion: High level of infused CD34+ appeared to be very opti-
mal for hematological recovery after ATSC in MM, without any sig-
nificant impact on O.S and PFS. An economical study is running on
this population to assess the impact of this level on hospitalization
and treatment costs, results will communicated in the future142
REVIEWING THE STATUS OF BACKUP HEMATOPOIETIC STEM CELLS
(HSC) BANKING FOR MULTIPLE MYELOMA (MM) PATIENTS WHO ARE
ELIGIBLE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELLS TRANS-
PLANT (AHSCT) IN THIS POOR ECONOMY
Abidi, M.H.1,2, Woldie, I.L.1, Goveas, R.1, Ratanatharathorn, V.1,2, Al-
Kadhimi, Z.1,2, Abrams, J.1,2, Ayash, L.1,2, Lum, L.1,2, Uberti, J.1,2
1Wayne State University, Detroit, MI; 2Karmanos Cancer Center, De-
troit, MI
Novel drugs combinations have demonstrated response rates
similar to AHSCT. Due to lack of long term follow up, impact
of these novel agents on HSC mobilization is unknown. AHSCT
is still standard therapy for newly diagnosed MM. There are ran-
domized trials underway to better define the role and timing of
AHSCT in MM. Due to this uncertainty with novel agents, arbi-
trary recommendations are made to cryopreserve backup stem
cells for pts who want to postpone AHSCT & to collect addi-
tional HSC at 1st HSC collection for future use. There is no con-
sensus on minimum duration of HSC cryopreservation, and this
can create significant financial,legal & logistical issues for stem
cell laboratories.
Methods: From 03/2000 to 06/2009, 270 MM pts were evaluated
for AHSCT at Karmanos Cancer Center, Detroit, MI. This review
was conducted to determine utilization of cryopreserved HSC for
a 2nd AHSCT at relapse/progression. No stem cells were collected
if the intent was not to offer AHSCT. Storage time was calculated as
the time between 1st & 2nd BMTs; as time between BMT & death &
as time between BMT & last follow-up for those known to be alive.
Results: Two hundred and fifty two eligible pts had HSC stored
with the intent to immediately proceed with at least a single AHSCT.
Seventeen pts (6.7%) received a 2nd transplant with progressive dis-
ease as the most common reason, tandem transplant and refractory
disease being other causes to perform delayed AHSCT. Significantly
more men than women received a second transplant. Differences in
age, race and stage of disease were not statistically significant. The
median CD 34+ cells dose collected was 8106/kg. A median 4.9
x106 CD 34+ cells/kg were infused; 26% (66/252) of pts had no cells
remaining after 1st transplant. Five (29%) of the 2nd transplants
were done during the 6 months following the first transplant. The re-
mainder occurred between 51 and 92 months following first trans-
plant.
